Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $7.9 million.

  • Amphastar Pharmaceuticals' Depreciation & Amortization (CF) fell 1973.86% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.8 million, marking a year-over-year decrease of 2050.69%. This contributed to the annual value of $28.2 million for FY2024, which is 976.03% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Depreciation & Amortization (CF) stood at $7.9 million, which was down 1973.86% from $8.3 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Depreciation & Amortization (CF) peaked at $9.8 million during Q3 2024, and registered a low of $2.5 million during Q1 2021.
  • Its 5-year average for Depreciation & Amortization (CF) is $5.7 million, with a median of $3.4 million in 2022.
  • The largest annual percentage gain for Amphastar Pharmaceuticals' Depreciation & Amortization (CF) in the last 5 years was 21589.94% (2024), contrasted with its biggest fall of 2484.47% (2024).
  • Amphastar Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $2.6 million in 2021, then skyrocketed by 32.28% to $3.4 million in 2022, then soared by 180.86% to $9.7 million in 2023, then decreased by 24.84% to $7.3 million in 2024, then rose by 8.31% to $7.9 million in 2025.
  • Its Depreciation & Amortization (CF) was $7.9 million in Q3 2025, compared to $8.3 million in Q2 2025 and $7.4 million in Q1 2025.